European regulators back cell-based flu vaccine

04/30/2007 | Reuters

The European Medicines Agency issued a positive opinion of Novartis AG's Optaflu, and full European marketing approval could come in two or three months. The new seasonal flu vaccine is made in cell cultures instead of chicken eggs, which the company says can speed production and allow for a faster manufacturing scale-up in case of a pandemic.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Sr. Principal Electrical Engineer - 14000008LR
San Jose, CA